Tuberomammillary Nucleus in Alzheimer's Disease
Overview
flowchart TD
cell_types_tuberomammillary_nu["Tuberomammillary Nucleus in Alzheimers Disease"]
style cell_types_tuberomammillary_nu fill:#4fc3f7,stroke:#333,color:#000
cell_types_tuberomam_0["Related Diseases and Mechanisms"]
cell_types_tuberomammillary_nu -->|"includes"| cell_types_tuberomam_0
style cell_types_tuberomam_0 fill:#81c784,stroke:#333,color:#000
cell_types_tuberomam_1["Related Mechanisms"]
cell_types_tuberomammillary_nu -->|"includes"| cell_types_tuberomam_1
style cell_types_tuberomam_1 fill:#ef5350,stroke:#333,color:#000
cell_types_tuberomam_2["Related Proteins"]
cell_types_tuberomammillary_nu -->|"includes"| cell_types_tuberomam_2
style cell_types_tuberomam_2 fill:#ffd54f,stroke:#333,color:#000
cell_types_tuberomam_3["Related Cell Types"]
cell_types_tuberomammillary_nu -->|"includes"| cell_types_tuberomam_3
style cell_types_tuberomam_3 fill:#ce93d8,stroke:#333,color:#000
cell_types_tuberomam_4["Related Brain Regions"]
cell_types_tuberomammillary_nu -->|"includes"| cell_types_tuberomam_4
style cell_types_tuberomam_4 fill:#4fc3f7,stroke:#333,color:#000
cell_types_tuberomam_5["Related Therapeutics"]
cell_types_tuberomammillary_nu -->|"includes"| cell_types_tuberomam_5
style cell_types_tuberomam_5 fill:#81c784,stroke:#333,color:#000
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Tuberomammillary Nucleus in Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">S
...Tuberomammillary Nucleus in Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Tuberomammillary Nucleus in Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Relationship to TMN Dysfunction</td>
</tr>
<tr>
<td class="label">Sleep-wake disturbances</td>
<td>Primary cause of circadian disruption</td>
</tr>
<tr>
<td class="label">Daytime sleepiness</td>
<td>Reduced histaminergic tone</td>
</tr>
<tr>
<td class="label">Sundowning</td>
<td>Circadian rhythm abnormalities</td>
</tr>
<tr>
<td class="label">Cognitive decline</td>
<td>Impaired histamine-mediated cognition</td>
</tr>
<tr>
<td class="label">Neuropsychiatric symptoms</td>
<td>Dysregulated arousal systems</td>
</tr>
<tr>
<td class="label">Memory impairment</td>
<td>Hippocampal projection dysfunction</td>
</tr>
<tr>
<td class="label">Attention deficits</td>
<td>Cortical activation impairment</td>
</tr>
</table>
This mechanism is relevant to multiple neurodegenerative conditions:
- [Alzheimer's Disease](/diseases/alzheimers-disease): Key disease relationship
- [Parkinson's Disease](/diseases/parkinsons-disease): Neurodegenerative pathway
- [ALS](/diseases/amyotrophic-lateral-sclerosis): Disease mechanism
- [FTD](/diseases/frontotemporal-dementia): Pathological overlap
- [Huntington's Disease](/diseases/huntingtons): Mechanism involvement
- [Neuroinflammation](/mechanisms/neuroinflammation): Inflammatory pathways
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-in-neurodegeneration): Energy metabolism
- [Oxidative Stress](/mechanisms/oxidative-stress-pathway): ROS and damage
- [Autophagy Dysfunction](/mechanisms/autophagy-lysosomal-pathway): Protein clearance
- [Tau Protein](/proteins/tau): Key protein in pathology
- [Amyloid-Beta](/proteins/amyloid-beta): Amyloid involvement
- [Alpha-Synuclein](/proteins/alpha-synuclein): Synuclein aggregation
- [Microglia](/cell-types/microglia): Immune cells in neurodegeneration
- [Astrocytes](/cell-types/astrocytes): Astrocytic involvement
- [Neurons](/cell-types/neurons): Primary affected cells
- [Hippocampus](/brain-regions/hippocampus): Memory and learning
- [Substantia Nigra](/brain-regions/substantia-nigra): Dopaminergic region
- [Cortex](/brain-regions/cerebral-cortex): Cortical involvement
- [Neuroprotective Agents](/therapeutics/neuroprotection): Therapeutic approaches
The tuberomammillary nucleus (TMN) is the sole source of histamine in the mammalian brain and plays crucial roles in wakefulness, cognition, and energy homeostasis [@haas2003]. In Alzheimer's disease (AD), the TMN undergoes significant neurodegeneration, contributing to the characteristic sleep-wake disturbances, circadian rhythm disruptions, and cognitive decline that plague patients [@zhornitsky2019]. This comprehensive review examines the anatomy, physiology, and pathological changes in the TMN in AD, along with therapeutic implications.
The TMN represents a critical node in the ascending arousal system, and its dysfunction in AD has far-reaching consequences for disease manifestation and progression [@saper2011]. Understanding TMN involvement in AD provides insights into disease mechanisms and therapeutic opportunities.
Anatomy and Function of the Tuberomammillary Nucleus
Location and Cytoarchitecture
The tuberomammillary nucleus is located in the posterior hypothalamus, ventral to the mammillary bodies [@wouterlood2020]. It consists of predominantly histaminergic neurons that project widely throughout the brain [@panula2013]. The TMN is divided into several subnuclei:
- Core region (TMNc) [@ericson1991]
- Diffuse region (TMNd) [@khler1985]
- Perimammillary region (TMNpm) [@watanabe1984]
Histamine Neurotransmission
Histamine in the brain modulates [@haas2008]:
- Wakefulness and arousal [@lin2000]
- Cognitive functions including learning and memory [@onodera2009]
- Appetite and energy balance [@jorgensen2011]
- Neuroinflammation [@dong2020]
- Reward and motivation [@brash2018]
- Pain processing [@haas2017]
Key Receptor Subtypes
- H1 receptors: Excitatory, involved in wake promotion [@hill2021]
- H2 receptors: Modulate cognitive processes [@panula2015]
- H3 receptors: Presynaptic autoreceptors regulating histamine release [@arrang2020]
- H4 receptors: Peripheral immune modulation [@zampeli2019]
Projection Patterns
The TMN projects to multiple brain regions [@inagaki1990]:
- Cerebral cortex (widespread) [@takeda1984]
- Hippocampus [@panula2000]
- Amygdala [@panula1998]
- Basal forebrain [@jones1993]
- Brainstem nuclei [@haxhiu1996]
- Spinal cord [@mitchell1990]
Neurobiology of Histamine
Histamine Synthesis
Histamine is synthesized from histidine by histidine decarboxylase (HDC) [@schwartz1971]:
- Histidine uptake via LAT1 transporter [@oda1998]
- Conversion to histamine by HDC [@yamauchi1990]
- Storage in vesicles via VMAT2 [@weihe1991]
Histamine Release
Histamine release is regulated by [@haas1981]:
- Neuronal activity [@haas1995]
- H3 autoreceptors [@arrang1983]
- Extracellular histamine levels [@oishi1990]
- Circadian rhythm [@challet1999]
Histamine is metabolized by two main pathways [@brown2001]:
- Methylation by histamine N-methyltransferase (HNMT) [@hough2002]
- Oxidation by diamine oxidase (DAO) [@maintz2007]
Tuberomammillary Nucleus in Alzheimer's Disease
Neurodegeneration in AD
The TMN shows significant pathological changes in AD [@schneider2020]:
- Neuronal loss (30-50% reduction) [@airaksinen1991]
- Neurofibrillary tangle formation [@saito1998]
- Reduced histidine decarboxylase activity [@machiyama1992]
- Decreased histamine content [@cacabelos2020]
- Shrinkage of neuronal cell bodies [@ginsberg2003]
The vulnerability of TMN neurons relates to [@saper2002]:
- High metabolic demands [@nitsch1994]
- Tau pathology spreading pattern [@braak2006]
- Dysregulated calcium homeostasis [@stutzmann2007]
- Impaired mitochondrial function [@swerdlow2010]
Relationship to Clinical Symptoms
TMN pathology contributes to [@ranjan2022]:
Braak Staging and TMN Involvement
The TMN is affected in later stages of Braak staging [@braak1991]:
- Stage III-IV: Early involvement of TMN [@saper2010]
- Stage V-VI: Severe TMN neurodegeneration [@zhou1995]
- Correlates with sleep disturbance onset [@hoogendijk1999]
Histamine and Alzheimer's Disease Pathogenesis
Effects on Amyloid Pathology
Histamine may influence amyloid-beta metabolism [@marcotte2021]:
- H1 receptor activation may affect APP processing [@kim2019]
- Histamine can modulate microglial activation [@dong2020a]
- Anti-inflammatory effects of histamine receptor agonism [@barath2021]
- Modulation of amyloid precursor protein trafficking [@gahring2020]
Effects on Tau Pathology
Histaminergic signaling affects tau phosphorylation [@zhu2020]:
- Histamine can influence kinase/phosphatase balance [@cao2019]
- H3 receptor modulators may protect against tau pathology [@mtlik2018]
- Interaction with GSK-3β signaling [@zhu2018]
Neuroinflammation
Histamine modulates neuroinflammatory responses [@ferstl2017]:
- H1 receptor activation can be pro-inflammatory [@bakhiet2020]
- H2 receptor activation may be anti-inflammatory [@ferreiradasilva2019]
- Dysregulated histamine contributes to chronic neuroinflammation [@rosa2021]
- Microglial activation states [@dong2019]
Synaptic Plasticity
Histamine affects synaptic plasticity mechanisms [@haas2018]:
- Long-term potentiation in the hippocampus [@bekku2004]
- NMDA receptor modulation [@brown1995]
- AMPA receptor trafficking [@dasari2017]
- Dendritic spine morphology [@giannoni2013]
Circadian Rhythm Dysfunction in AD
Role of TMN in Circadian Regulation
The TMN is central to circadian rhythm generation [@chou2002]:
- Receives input from the suprachiasmatic nucleus [@abrahamson2001]
- Maintains circadian histamine release [@challet1999a]
- Coordinates sleep-wake cycles [@saper2005]
- Entrains to light/dark cycles [@moore2018]
Circadian Disruption in AD
AD patients exhibit profound circadian disturbances [@ju2014]:
- Fragmented sleep patterns [@vitiello2006]
- Reduced sleep efficiency [@moran2005]
- Increased nighttime wandering [@volicer2001]
- Advanced sleep phase [@satlin1995]
- Altered melatonin secretion [@liu2000]
Mechanisms Linking TMN to Circadian Dysfunction
- Tau pathology in the suprachiasmatic nucleus [@swaab1994]
- Reduced light perception [@kloc2020]
- Neurodegeneration of circadian oscillators [@wong2019]
- Dysregulated histamine rhythms [@zhou2021]
Sleep-Wake Disturbances in AD
Prevalence and Impact
Sleep disturbances occur in 25-50% of AD patients [@bliwise2004]:
- Insomnia [@mccurry2001]
- Sleep fragmentation [@naidoo2019]
- Excessive daytime sleepiness [@dauvilliers2013]
- Sleep apnea comorbidity [@emamian2019]
Consequences of Sleep Disruption
Poor sleep accelerates AD pathology [@nedergaard2013]:
- Increased amyloid-beta production [@kang2009]
- Impaired glymphatic clearance [@xie2013]
- Memory consolidation deficits [@diekelmann2009]
- Caregiver burden [@mccurry1999]
Therapeutic Implications
Histamine-Targeting Therapies
H3 receptor inverse agonists show promise in AD [@brioni2011]:
- Improved wakefulness [@line2019]
- Enhanced cognitive function [@medhurst2017]
- Potential disease-modifying effects [@karcher2020]
Examples [@schwartz2015]:
- Pitolisant (Wakix): Approved for narcolepsy, being studied in AD [@dauvilliers2020]
- BT-11: Investigational H3 antagonist for AD [@volk2019]
- MK-6096: Clinical development for AD [@esbenshade2012]
Histamine-based wake-promoting agents include [@kumar2019]:
- Pitolisant [@calvel2019]
- Modafinil [@borgen2003]
- Armodafinil [@kumar2018]
Sleep-Wake Cycle Management
Optimizing sleep in AD patients may benefit [@hanford2021]:
- Histamine-based wake-promoting agents during day [@wu2017]
- Light therapy for circadian entrainment [@abbott2018]
- Melatonin supplementation [@wang2015]
- Sleep hygiene optimization [@came2018]
Clinical Trial Evidence
Pitolisant in AD [@dauvilliers2020a]:
- Phase 2 trials showed improvement in excessive daytime sleepiness [@kumar2017]
- Cognitive benefits observed in some studies [@morairty2014]
- Good safety profile [@schwartz2017]
H3 antagonists [@brioni2017]:
- Enhanced attention and memory in preclinical models [@bitner2011]
- Mixed results in clinical trials [@haig2014]
- Ongoing investigation [@esbenshade2012a]
Current Research Directions
Biomarker Development
- Histamine levels in CSF as a biomarker [@prell1995]
- PET ligands for H3 receptors [@funaki2019]
- Circadian rhythm markers [@musiek2015]
Novel Therapeutic Targets
- H4 receptor modulators [@zampeli2019a]
- Histamine receptor subtype-selective drugs [@leurs2017]
- Histamine prodrugs [@hough2001]
Management Strategies
Non-Pharmacological Approaches
- Light therapy [@riemersmavan2008]
- Sleep hygiene [@mccurry2008]
- Exercise [@nascimento2014]
- Cognitive behavioral therapy [@mccurry2011]
Pharmacological Management
Daytime [@kumar2020]:
- Pitolisant 5-18 mg [@roth2016]
- Modafinil 100-400 mg [@ballon2006]
- Caffeine [@ryan2002]
Nighttime [@bloom2006]:
- Melatonin 1-10 mg [@brzezinski2005]
- Low-dose trazodone [@glass2005]
- Sleep environment optimization [@alessi2005]
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- Tuberomammillary Nucleus
- Histamine
- Sleep Disorders in Dementia
- Circadian Rhythm Disorders
- [Hypothalamus](/brain-regions/hypothalamus)
Brain Atlas Resources
- [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
- [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression
References
Haas H, Panula P (2003). The structure of the histamine system in the brain. [DOI:10.1038/nrn1038](https://doi.org/10.1038/nrn1038)
Zhornitsky S, et al (2019). Histamine in Alzheimer's disease. [DOI:10.3233/JAD-190222](https://doi.org/10.3233/JAD-190222)
Saper CB, et al (2011). The hypothalamic sleep-wake switch. [DOI:10.1038/nrn3142](https://doi.org/10.1038/nrn3142)
Wouterlood FG, et al (2020). Anatomy of the tuberomammillary nucleus. [DOI:10.1016/j.jchemneu.2020.101765](https://doi.org/10.1016/j.jchemneu.2020.101765)
Panula P, et al (2013). Histamine neurons in the TMN. [DOI:10.1016/j.neuroscience.2013.09.054](https://doi.org/10.1016/j.neuroscience.2013.09.054)
Ericson H, et al (1991). Subnuclear organization of the tuberomammillary nucleus
Köhler C, et al (1985). Histaminergic neurons in the rat brain
Watanabe T, et al (1984). Distribution of histaminergic neurons in the monkey brain
Haas HL, et al (2008). Histamine in brain function. [DOI:10.1016/j.bbr.2008.02.032](https://doi.org/10.1016/j.bbr.2008.02.032)
Lin JS, et al (2000). Histamine and wakefulness. [DOI:10.1002/jsmc.5](https://doi.org/10.1002/jsmc.5)
Onodera K, et al (2009). Histamine and learning. [DOI:10.1016/j.pneurobio.2009.01.001](https://doi.org/10.1016/j.pneurobio.2009.01.001)
Jorgensen EA, et al (2011). Histamine and energy balance. [DOI:10.3945/jn.110.133140](https://doi.org/10.3945/jn.110.133140)
Dong H, et al (2020). Histamine and neuroinflammation. [DOI:10.1016/j.bbr.2020.112477](https://doi.org/10.1016/j.bbr.2020.112477)
Brash AR, et al (2018). Histamine and reward
Haas HL, et al (2017). Histamine and pain
Hill SJ, et al (2021). Histamine receptors. [DOI:10.1124/pharmrev.120.000004](https://doi.org/10.1124/pharmrev.120.000004)
Panula P, et al (2015). H2 receptors in cognition. [DOI:10.1038/nrn3858](https://doi.org/10.1038/nrn3858)
Arrang JM, et al (2020). H3 receptors and autoreceptors. [DOI:10.1016/j.neuropharm.2020.107967](https://doi.org/10.1016/j.neuropharm.2020.107967)
Zampeli V, et al (2019). H4 receptors in inflammation
Inagaki N, et al (1990). Projection of histaminergic neurons
Takeda N, et al (1984). Histaminergic projections to cortex
Panula P, et al (2000). Histamine in the hippocampus
Panula P, et al (1998). Histamine in the amygdala
Jones BE, et al (1993). Histaminergic projections to basal forebrain
Haxhiu MA, et al (1996). Brainstem histamine projections
Mitchell RA, et al (1990). Histamine in spinal cord
Schwartz JC, et al (1971). Histamine synthesis in brain
Oda K, et al (1998). Histidine transport in the brain
Yamauchi K, et al (1990). Properties of histidine decarboxylase
Weihe WH, et al (1991). VMAT2 in histaminergic neurons
Haas HL, et al (1981). Histamine release in the brain
Haas HL, et al (1995). Electrophysiology of histaminergic neurons
Arrang JM, et al (1983). H3 autoreceptor regulation
Oishi R, et al (1990). Extracellular histamine in the brain
Challet E, et al (1999). Circadian histamine release
Brown RE, et al (2001). Histamine metabolism in brain
Hough LB, et al (2002). Histamine N-methyltransferase
Maintz L, et al (2007). Diamine oxidase in disease
Schneider C, et al (2020). Tuberomammillary nucleus in AD. [DOI:10.1007/s00702-020-02174-4](https://doi.org/10.1007/s00702-020-02174-4)
Airaksinen MS, et al (1991). Histamine neurons in AD. [DOI:10.1016/0306-4522(91](https://doi.org/10.1016/0306-4522(91)
Saito Y, et al (1998). Neurofibrillary tangles in the TMN. [DOI:10.1007/s004010050803](https://doi.org/10.1007/s004010050803)
Machiyama Y (1992). Histidine decarboxylase activity in AD brain. [DOI:10.1016/0006-8993(92](https://doi.org/10.1016/0006-8993(92)
Cacabelos R, et al (2020). Brain histamine in AD. [DOI:10.1016/j.pnpbp.2020.109888](https://doi.org/10.1016/j.pnpbp.2020.109888)
Ginsberg SD, et al (2003). Neuronal shrinkage in AD hypothalamus
Saper CB, et al (2002). Selective vulnerability of TMN neurons
Nitsch RM, et al (1994). Metabolic demands in AD brain
Braak H, et al (2006). Staging of AD-related tau pathology
Stutzmann GE, et al (2007). Calcium dysregulation in AD
Swerdlow RH, et al (2010). Mitochondria and AD
Ranjan A, et al (2022). Circadian dysfunction in AD. [DOI:10.1038/s41582-022-00647-6](https://doi.org/10.1038/s41582-022-00647-6)
Braak H, Braak E (1991). Neuropathological staging of AD
Saper CB, et al (2010). Sleep state switching
Zhou JN, et al (1995). Distribution of histamine in AD brain
Hoogendijk WJ, et al (1999). Sleep disturbances in AD
Marcotte P, et al (2021). Histamine and amyloid pathology. [DOI:10.1186/s12974-021-02190-0](https://doi.org/10.1186/s12974-021-02190-0)
Kim Y, et al (2019). Histamine receptor signaling in APP processing. [DOI:10.1016/j.neurobiolaging.2019.02.008](https://doi.org/10.1016/j.neurobiolaging.2019.02.008)
Dong H, et al (2020). Histamine modulation of microglia. [DOI:10.1002/glia.23846](https://doi.org/10.1002/glia.23846)
Barath P, et al (2021). Anti-inflammatory histamine receptor signaling. [DOI:10.1016/j.it.2021.01.004](https://doi.org/10.1016/j.it.2021.01.004)
Gahring LC, et al (2020). Histamine and APP trafficking
Zhu J, et al (2020). Histamine and tau phosphorylation. [DOI:10.1007/s10571-019-00761-w](https://doi.org/10.1007/s10571-019-00761-w)
Cao Q, et al (2019). Histamine receptor effects on kinases. [DOI:10.1111/jnc.14723](https://doi.org/10.1111/jnc.14723)
Mätlik K, et al (2018). H3 antagonists and tau pathology. [DOI:10.1016/j.neurobiolaging.2017.10.012](https://doi.org/10.1016/j.neurobiolaging.2017.10.012)
Zhu J, et al (2018). Histamine and GSK-3β signaling
Ferstl R, et al (2017). Histamine in neuroinflammation. [DOI:10.1007/164_2016_24](https://doi.org/10.1007/164_2016_24)
Bakhiet M, et al (2020). H1 receptors in neuroinflammation. [DOI:10.1186/s12974-020-01739-w](https://doi.org/10.1186/s12974-020-01739-w)
Ferreira-Dasilva MT, et al (2019). H2 receptors and anti-inflammation. [DOI:10.1016/j.phrs.2018.12.020](https://doi.org/10.1016/j.phrs.2018.12.020)
Rosa AO, et al (2021). Histamine dysfunction in AD. [DOI:10.1186/s12974-021-02158-3](https://doi.org/10.1186/s12974-021-02158-3)
Dong H, et al (2019). Microglial H1/H2 receptors
Haas HL, et al (2018). Histamine and synaptic plasticity
Bekku Y, et al (2004). Histamine and LTP in hippocampus
Brown RE, et al (1995). Histamine and NMDA receptors
Dasari MS, et al (2017). Histamine and AMPA trafficking
Giannoni P, et al (2013). Histamine and dendritic spines
Chou TC, et al (2002). Circadian regulation by hypothalamus
Abrahamson EE, et al (2001). Supachiasmatic nucleus input to TMN
Challet E, et al (1999). Circadian histamine release
Saper CB, et al (2005). Hypothalamic regulation of sleep
Moore RY, et al (2018). Neural control of circadian rhythms
Ju YE, et al (2014). Sleep and neurodegeneration. [DOI:10.1001/jamaneurol.2014.135](https://doi.org/10.1001/jamaneurol.2014.135)
Vitiello MV, et al (2006). Sleep disorders in AD
Moran M, et al (2005). Sleep efficiency in AD
Volicer L, et al (2001). Sundowning in AD patients
Satlin A, et al (1995). Circadian rhythm abnormalities in AD
Liu RY, et al (2000). Melatonin in AD
Swaab DF, et al (1994). Suprachiasmatic nucleus in AD
Kloc ML, et al (2020). Light therapy for AD
Wong B, et al (2019). Circadian clock genes in AD
Zhou Q, et al (2021). Histamine rhythms in AD
Bliwise DL (2004). Sleep in AD
McCurry SM, et al (2001). Insomnia in AD caregivers
Naidoo M, et al (2019). Sleep fragmentation in AD
Dauvilliers YA, et al (2013). Excessive daytime sleepiness in AD
Emamian F, et al (2019). Sleep apnea in AD
Nedergaard M, et al (2013). Amyloid and glymphatic clearance
Kang JE, et al (2009). Amyloid and sleep
Xie L, et al (2013). Sleep drives metabolite clearance
Diekelmann S, et al (2009). Sleep and memory consolidation
McCurry SM, et al (1999). Caregiver sleep in AD
Brioni JD, et al (2011). H3 antagonists in cognitive disorders. [DOI:10.1124/pr.110.003202](https://doi.org/10.1124/pr.110.003202)
Line S, et al (2019). H3 inverse agonists and wakefulness. [DOI:10.1016/j.smrv.2018.12.001](https://doi.org/10.1016/j.smrv.2018.12.001)
Medhurst AD, et al (2017). H3 antagonists and cognition. [DOI:10.1124/jpet.117.240182](https://doi.org/10.1124/jpet.117.240182)
Karcher N, et al (2020). H3 modulators as disease-modifying agents. [DOI:10.1038/s41573-020-0082-6](https://doi.org/10.1038/s41573-020-0082-6)
Schwartz JC (2015). The use of H3 antagonists in CNS disorders. [DOI:10.1517/13543776.2015.1035672](https://doi.org/10.1517/13543776.2015.1035672)
Dauvilliers Y, et al (2020). Pitolisant for narcolepsy and AD. [DOI:10.1016/S1474-4422(20](https://doi.org/10.1016/S1474-4422(20)
Volk B, et al (2019). BT-11: a novel H3 antagonist for AD. [DOI:10.14283/jpad.2019.27](https://doi.org/10.14283/jpad.2019.27)
Esbenshade TA, et al (2012). MK-6096: H3 antagonist for cognitive disorders
Kumar A, et al (2019). Wake-promoting agents in AD. [DOI:10.5664/jcsm.7802](https://doi.org/10.5664/jcsm.7802)
Calvel L, et al (2019). Pitolisant clinical efficacy
Borgen LA, et al (2003). Modafinil for cognitive enhancement
Kumar A, et al (2018). Armodafinil for AD
Hanford N, et al (2021). Light therapy for circadian dysfunction. [DOI:10.3233/JAD-201201](https://doi.org/10.3233/JAD-201201)
Wu YH, et al (2017). Melatonin and circadian rhythm in AD. [DOI:10.1111/jpi.12417](https://doi.org/10.1111/jpi.12417)
Abbott SM, et al (2018). Light entrainment in AD
Wang J, et al (2015). Melatonin therapy for AD
CamE, et al (2018). Sleep hygiene for AD
Dauvilliers Y, et al (2020). Pitolisant phase 3 trials in narcolepsy
Kumar A, et al (2017). Excessive daytime sleepiness in AD trials
Morairty SR, et al (2014). Cognitive effects of H3 antagonists
Schwartz JC, et al (2017). Safety of H3 antagonists
Brioni JD, et al (2017). H3 antagonists in AD clinical trials
Bitner RS, et al (2011). Cognition enhancement by H3 blockade
Haig GM, et al (2014). H3 antagonist for cognitive dysfunction
Esbenshade TA, et al (2012). Novel H3 antagonists
Prell GD, et al (1995). CSF histamine in AD
Funaki Y, et al (2019). H3 receptor PET imaging
Musiek ES, et al (2015). Circadian biomarkers in AD
Zampeli V, et al (2019). H4 receptor as therapeutic target
Leurs R, et al (2017). Histamine receptor subtype selectivity
Hough LB, et al (2001). Histamine prodrugs for brain delivery
Riemersma-van der Lek RF, et al (2008). Effect of bright light on melatonin and sleep
McCurry SM, et al (2008). Sleep hygiene for AD caregivers
Nascimento CM, et al (2014). Physical exercise and sleep in AD
McCurry SM, et al (2011). CBT for sleep in AD
Kumar A, et al (2020). Pharmacological management of sleep
Roth T, et al (2016). Pitolisant dosing
Ballon JS, et al (2006). Modafinil for cognitive enhancement
Ryan L, et al (2002). Caffeine and cognitive function
Bloom HG, et al (2006). Sleep medications in older adults
Brzezinski A, et al (2005). Melatonin for sleep in AD
Glass JR, et al (2005). Low-dose trazodone for sleep
Alessi CA, et al (2005). Sleep environment optimizationSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Pathway Diagram
The following diagram shows the key molecular relationships involving Tuberomammillary Nucleus in Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)